Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

TAS‐120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure
Maria Kalyukina, Y. Yosaatmadja, Martin Middleditch, et al.
ChemMedChem (2019) Vol. 14, Iss. 4, pp. 494-500
Closed Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 321
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley, John Bridgewater, Gregory J. Gores, et al.
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 353-363
Open Access | Times Cited: 320
Futibatinib for FGFR2 -Rearranged Intrahepatic Cholangiocarcinoma
Lipika Goyal, Funda Meric‐Bernstam, Antoine Hollebecque, et al.
New England Journal of Medicine (2023) Vol. 388, Iss. 3, pp. 228-239
Open Access | Times Cited: 318
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance
Melanie A. Krook, Julie W. Reeser, Gabrielle Ernst, et al.
British Journal of Cancer (2020) Vol. 124, Iss. 5, pp. 880-892
Open Access | Times Cited: 256
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai, Zhan Zhou, Zhuchu Chen, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 614-614
Open Access | Times Cited: 245
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 242
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study
Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, et al.
Cancer Discovery (2021) Vol. 12, Iss. 2, pp. 402-415
Open Access | Times Cited: 200
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito, et al.
Cancer Research (2020) Vol. 80, Iss. 22, pp. 4986-4997
Open Access | Times Cited: 155
Targeting FGFR inhibition in cholangiocarcinoma
Lipika Goyal, Sarinya Kongpetch, Valerie Crolley, et al.
Cancer Treatment Reviews (2021) Vol. 95, pp. 102170-102170
Open Access | Times Cited: 137
New developments in the biology of fibroblast growth factors
David M. Ornitz, Nobuyuki Itoh
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 4
Open Access | Times Cited: 96
The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer
J.E. Berchuck, Francesco Facchinetti, Daniel DiToro, et al.
Annals of Oncology (2022) Vol. 33, Iss. 12, pp. 1269-1283
Open Access | Times Cited: 86
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
Vivek Subbiah, Vaibhav Sahai, Dejan Maglic, et al.
Cancer Discovery (2023) Vol. 13, Iss. 9, pp. 2012-2031
Open Access | Times Cited: 69
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
Heike Schönherr, Pelin Ayaz, Alexander M. Taylor, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 6
Open Access | Times Cited: 22
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
Rastislav Bahleda, Funda Meric‐Bernstam, Lipika Goyal, et al.
Annals of Oncology (2020) Vol. 31, Iss. 10, pp. 1405-1412
Open Access | Times Cited: 128
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 116
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
Melanie A. Krook, Alexandria Lenyo, Max Wilberding, et al.
Molecular Cancer Therapeutics (2020) Vol. 19, Iss. 3, pp. 847-857
Open Access | Times Cited: 114
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 764-774
Open Access | Times Cited: 105
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
Antonella De Luca, Riziero Esposito Abate, Anna Maria Rachiglio, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6856-6856
Open Access | Times Cited: 99
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
Xiaoyun Lu, Jeff B. Smaill, Adam V. Patterson, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 1, pp. 58-83
Closed Access | Times Cited: 90
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi
Expert Opinion on Investigational Drugs (2020) Vol. 30, Iss. 4, pp. 317-324
Open Access | Times Cited: 84
Futibatinib: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 18, pp. 1737-1743
Open Access | Times Cited: 49
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 36
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, et al.
Cells (2023) Vol. 12, Iss. 7, pp. 1002-1002
Open Access | Times Cited: 30
The role of the methoxy group in approved drugs
Debora Chiodi, Yoshihiro Ishihara
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116364-116364
Closed Access | Times Cited: 16
Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 690-690
Open Access | Times Cited: 71
Page 1 - Next Page

Scroll to top